STAT+: GLP-1s are given an FDA warning for rare eye condition risk
No detailed data were disclosed, but Beam said it would file an FDA marketing application for the therapy, called risto-cel, as soon as the end of this year.
Key points
- Continue to STAT+ to read the full story….
- Want to stay on top of the science and politics driving biotech today?
- Sign up to get our biotech newsletter in your inbox.
The need-to-know this morning Beam Therapeutics said its CRISPR-based treatment for sickle cell disease achieved the primary goal of a pivotal clinical trial — freedom from severe pain crises for at least 12 months.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.